Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 10/20 | 0.80 |
| ▸ | AKT2 | P31751 | 7/20 | 0.80 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.80 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.80 |
| ▸ | PRKACA | P17612 | 2/20 | 0.80 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.80 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.80 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.80 |
| ▸ | LATS1 | O95835 | 1/20 | 0.80 |
| ▸ | PRKACB | P22694 | 1/20 | 0.80 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.80 |
| ▸ | GRK2 | P25098 | 1/20 | 0.80 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.80 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.80 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.80 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.80 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.80 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.80 |
| ▸ | SGK3 | Q96BR1 | 1/20 | 0.80 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3028412 | 1.00 | AKT1 (0.80) | AKT1AKT2ROCK2AKT3PRKACA | |
| SCHEMBL3024761 | 1.00 | AKT1 (0.80) | AKT1AKT2ROCK2AKT3PRKACA | |
| SCHEMBL3030502 | 0.92 | AKT1 (0.76) | AKT1AKT2ROCK2AKT3PRKACA | |
| At-13148 SCHEMBL850592 | 0.89 | AKT1 (1.00) | AKT1AKT2ROCK2AKT3PRKACA | |
| At-13148 SCHEMBL851075 | 0.89 | AKT1 (1.00) | AKT1AKT2ROCK2AKT3PRKACA | |
| At-13148 SCHEMBL851471 | 0.89 | AKT1 (1.00) | AKT1AKT2ROCK2AKT3PRKACA | |
| SCHEMBL3025800 | 0.89 | AKT1 (0.64) | AKT1AKT2ROCK2AKT3PRKACA | |
| SCHEMBL3019393 | 0.88 | AKT1 (0.66) | AKT1AKT2ROCK2AKT3PRKACA | |
| SCHEMBL3021514 | 0.88 | AKT2 (0.62) | AKT1AKT2ROCK2AKT3PRKACA | |
| At-13148 SCHEMBL15134882 | 0.88 | AKT1 (0.97) | AKT1AKT2ROCK2AKT3PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | claimed |
| EP-1904451-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2008-04-02 | — | — | EP | claimed |
| WO-2006136830-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | claimed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| EP-1904451-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006136830-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ERBB2, ABL1, GRK2 | AKT1 73/4885AKT2 88/4885ROCK2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.